AnaptysBio Stock

AnaptysBio Market capitalization 2024

AnaptysBio Market capitalization

943.15 M USD

Ticker

ANAB

ISIN

US0327241065

WKN

A2AJ8C

In 2024, AnaptysBio's market cap stood at 943.15 M USD, a 90.77% increase from the 494.38 M USD market cap in the previous year.

The AnaptysBio Market capitalization history

YEARMarket Capitalization (undefined USD)
20230.54
20220.73
20210.71
20200.52
20191.43
20182.18
20170.76
2016-
2015-
2014-
2013-

AnaptysBio Aktienanalyse

What does AnaptysBio do?

AnaptysBio Inc is a biopharmaceutical company founded in 2005 and headquartered in San Diego, California. The company focuses on researching, developing, and marketing novel therapeutic antibodies for the treatment of autoimmune diseases, inflammation, and cancer. AnaptysBio has a unique business model that aims to make antibody development more efficient and cost-effective. Instead of relying on traditional methods like the hybridoma technique, the company uses its proprietary SHM-XEL technology to isolate and identify human antibodies directly from B cells. This approach allows AnaptysBio to quickly find, test, and optimize high-quality antibody candidates, resulting in significantly shorter development times and lower costs. The company has two main divisions. The first division focuses on the development of antibodies for the treatment of autoimmune diseases and inflammation. In this division, AnaptysBio has several promising antibody candidates in its pipeline, including ANB020, an antibody against the immune system protein IL-33, being developed for the treatment of asthma and other allergic diseases. ANB019, an antibody against the immune system protein IL-36R, being developed for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis, is another promising candidate. The second division of AnaptysBio focuses on the development of antibodies for the treatment of cancer. Here, the company has formed a promising partnership with TESARO, a leading cancer therapy company. Together, they are developing an antibody called TSR-042 that targets the immune system protein PD-1 and is used for the treatment of various cancers such as lung cancer and bladder cancer. AnaptysBio also has several products on the market that are based on its proprietary SHM-XEL technology. These include Simponi (Golimumab), an antibody used for rheumatoid arthritis, Crohn's disease, and psoriasis, for which AnaptysBio developed the technology in partnership with Janssen Biotech. Over the years, AnaptysBio has received several significant awards and recognition for its innovative antibody development platforms and technologies. In 2017, the company was included in the Deloitte Technology Fast 500 list and received the Frost & Sullivan Technology Innovation Award for its SHM-XEL technology. Overall, AnaptysBio is an innovative biopharmaceutical company with a unique business model and a promising pipeline of antibody candidates for the treatment of autoimmune diseases, inflammation, and cancer. Through its proprietary technology and partnerships with other companies, AnaptysBio remains well-positioned to continue providing innovative therapeutic solutions for patients. AnaptysBio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring AnaptysBio's Market Capitalization

AnaptysBio's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of AnaptysBio's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

AnaptysBio's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in AnaptysBio’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about AnaptysBio stock

What is the current AnaptysBio market capitalization?

The current market capitalization of AnaptysBio is 943.15 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like AnaptysBio.

How has the market capitalization of AnaptysBio developed in recent years?

The market capitalization of AnaptysBio has increased/decreased by 90.77% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of AnaptysBio?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of AnaptysBio?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of AnaptysBio have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does AnaptysBio pay?

Over the past 12 months, AnaptysBio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnaptysBio is expected to pay a dividend of 0 USD.

What is the dividend yield of AnaptysBio?

The current dividend yield of AnaptysBio is .

When does AnaptysBio pay dividends?

AnaptysBio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AnaptysBio?

AnaptysBio paid dividends every year for the past 0 years.

What is the dividend of AnaptysBio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AnaptysBio located?

AnaptysBio is assigned to the 'Health' sector.

Wann musste ich die Aktien von AnaptysBio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AnaptysBio from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did AnaptysBio pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of AnaptysBio in the year 2023?

In the year 2023, AnaptysBio distributed 0 USD as dividends.

In which currency does AnaptysBio pay out the dividend?

The dividends of AnaptysBio are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von AnaptysBio

Our stock analysis for AnaptysBio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnaptysBio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.